Prognostic impact of genomic instability in colorectal cancer

T S Hveem1,2,3, M A Merok2,4,5, M E Pretorius1,2, M Novelli2,6, M S Bævre1,2, O H Sjo7, N Clinch1, K Liestøl2,3, A Svinland5,8, R A Lothe2,4,5, A Nesbakken2,5,7 and H E Danielsen1,2,3,9

1Institute for Cancer Genetics and Informatics, Oslo University Hospital, PO Box 4950 Nydalen, 0424 Oslo, Norway; 2Centre for Cancer Biomedicine, University of Oslo, PO Box 4950 Nydalen, 0424 Oslo, Norway; 3Department of Informatics, University of Oslo, PO Box 1080 Blindern, 0316 Oslo, Norway; 4Department of Cancer Prevention, Institute for Cancer Research, Oslo University Hospital, PO Box 4953 Nydalen, 0424 Oslo, Norway; 5Institute of Clinical Medicine, University of Oslo, PO Box 1171 Blindern, 0318 Oslo, Norway; 6Department of Pathology, University College Hospital, London WC1E 6JJ, UK; 7Department of Gastrointestinal Surgery, Oslo University Hospital, PO Box 4950 Nydalen, 0424 Oslo, Norway; 8Department of Pathology, Oslo University Hospital, PO Box 4950 Nydalen, 0424 Oslo, Norway and 9Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, UK

Background: The prognostic impact of an indication of chromosomal instability (CIN) is evaluated in a consecutive series of 952 colorectal cancer patients treated at Aker University Hospital, Norway, during 1993–2003. Microsatellite instability (MSI) in this case series has recently been reported and made it possible to find the co-occurrence and compare the prognostic significance of CIN and MSI.

Methods: Data sets for overall survival (OS; n = 855) and time to recurrence (TTR; n = 579) were studied. To reveal CIN we used automated image cytometry (ICM). Non-diploid histograms were taken as indicative of the presence of CIN. PCR-based measures of MSI in this material have already been described.

Results: As with MSI, CIN was found to be an independent predictor of early relapse and death among stage II patients (TTR: n = 278: HR 2.19 (95% CI: 1.35–3.55), P = 0.002). Of the MSI tumours (16%), 71% were found to be DNA diploid, 21% were DNA tetraploid and 8% were DNA aneuploid. Among microsatellite stable tumours, 24% were DNA diploid, 15% were DNA tetraploid and 61% were DNA aneuploid.

Conclusion: For patients presenting with stage II disease, genomic instability as detected by DNA image cytometry has the potential to provide a useful biomarker for relapse and cancer-related death following surgery with curative intent.

For primary adenocarcinomas of the colon or rectum, tumour stage is still the best predictor of survival after resection. However, among patients diagnosed with UICC stage II (pT3–pT4, N0, M0) colorectal cancer (CRC), up to 35% will experience recurrence (Staab et al, 2002; Jemal et al, 2004). Several molecular and gene-expression profiling biomarkers have been proposed as markers of poor prognosis in stage II patients, but none has yet been validated in a large-scale prospective clinical trial (Barrier et al, 2007; Gangadhar and Schilsky, 2010; Ågesen et al, 2012). We report on the stage-dependent prognostic significance of chromosomal instability (CIN) and microsatellite instability (MSI) in a large consecutive series of colorectal carcinomas treated in one hospital with a defined catchment area.

DNA aneuploidy, an accepted marker for CIN, is found in the majority of sporadic CRC and has been linked to poor prognosis (Lengauer et al, 1998; Mouradov et al, 2013). Two recent meta-analyses of 67 separate studies demonstrated poorer overall survival (OS) for patients with stage II–III colorectal tumours showing CIN (HR 1.45 (1.33–1.55)) (Araujo et al, 2007; Walther et al, 2008).

Microsatellite instability is a marker for relatively good prognosis in CRC, also supported by meta-analysis (Guastadisegni et al, 2010).

*Correspondence: Professor HE Danielsen; E-mail: hdaniels@labmed.uio.no

Received 16 December 2013; revised 18 February 2014; accepted 18 February 2014; published online 18 March 2014

© 2014 Cancer Research UK. All rights reserved 0007–0920/14
In this study we have had access to data from a recent PCR study of the occurrence of MSI in the present material (Merok et al, 2013). Traditionally, CIN and MSI have been seen as different and complementary pathways to CRC. However, studies including other biomarkers have shown that the picture is more complicated (Toyota et al, 1999; Hawkins et al, 2001; Domingo et al, 2013). This is the first study to examine the stage-related prognostic impacts of CIN and MSI together in one large consecutive patient series.

**MATERIAL AND METHODS**

**Patient data.** This study is based on consecutive primary CRCs referred to Aker University Hospital in Oslo, Norway, from 1993 to 2003. The series comprised 1274 patients out of which 952 underwent major resection. Median age at presentation was 74 (19–96) years. Details of preoperative investigations, operative procedures, histopathological examinations, patient follow-up and mortality data have been reported previously (Nesbakken et al, 2002; Sjo et al, 2008).

**Exclusions.** We excluded 44 patients who died of post-operative complications and 53 cases where the nuclear monolayer or DNA content histograms were unsatisfactory, resulting in a data set containing crude OS, clinical data and DNA content histograms for 855 colorectal adenocarcinomas at stages I–IV.

**Recurrence analysis.** For time to recurrence (TTR) analysis, a further restricted data set (n = 579) was prepared by eliminating patients presenting with metastatic disease, residual cancer (R>0), unknown cause of death or synchronous lesions (Punt et al, 2007). Median patient age at surgery was 73 years (30–94).

**Tumour location.** Tumours located proximal to the splenic flexure were considered as proximal (right), while tumours located at or distal to the splenic flexure were considered to be distal (left). Supplementary Table S1 shows the anatomical distribution of tumours in the TTR data set.

**Tissue processing and DNA ploidy measurement.** Automated image-based DNA cytometry was performed as previously described (Kristensen et al, 2003). Nuclear DNA content histograms were classified as DNA diploid, DNA tetraploid or DNA aneuploid. Non-diploid histograms were taken as indicative of the presence of CIN.

**Microsatellite instability assessment.** Details of PCR MSI determination in this material were recently described (Merok et al, 2013).

**Statistical analysis.** Overall survival was computed in months from the date of surgery until death or May 2010. Death from any cause was registered as an event (data from the Norwegian Death Registry). Living patients were censored at the end of the study (mean follow-up: 69 months). In analyses of TTR, local or distant recurrence or death from CRC were registered as events, and patients were censored at death from other causes or at study closure.

Significance of associations between categorical variables was evaluated using Fisher’s exact test. The Mantel-Cox log-rank test was used for univariate analysis. For multivariate evaluation of

---

**Table 1. Clinicopathological data for the time to recurrence data set**

| Variables      | All tumours | DNA diploid | DNA non-diploid |
|----------------|-------------|-------------|-----------------|
|                | n    | %   | n    | %   | n    | %   |
| Relapse        | 220  | 38.0| 55   | 30.1| 165  | 41.7|
| No relapse     | 359  | 62.0| 128  | 69.9| 231  | 58.3|
| MSI status     |        |      |      |     |      |     |
| MSS            | 452  | 83.9| 108  | 63.5| 344  | 93.2|
| MSI            | 87   | 16.1| 62   | 36.5| 25   | 6.8 |
| Age at surgery (years) | | | | |
| ≤72            | 289  | 49.9| 92   | 50.3| 197  | 49.7|
| >72            | 290  | 50.1| 91   | 49.7| 199  | 50.3|
| Gender         |        |      |      |     |      |     |
| Male           | 289  | 49.9| 75   | 41.0| 214  | 54.0|
| Female         | 290  | 50.1| 108  | 59.0| 182  | 46.0|
| Stage          |        |      |      |     |      |     |
| I              | 112  | 19.3| 37   | 20.2| 75   | 18.9|
| II             | 278  | 48.0| 96   | 52.5| 182  | 46.0|
| III            | 189  | 32.6| 50   | 27.3| 139  | 35.1|
| pT status      |        |      |      |     |      |     |
| pT1            | 27   | 4.7 | 10   | 5.5 | 17   | 4.3 |
| pT2            | 103  | 17.8| 32   | 17.5| 71   | 17.9|
| pT3            | 415  | 71.7| 135  | 73.8| 280  | 70.7|
| pT4            | 34   | 5.9 | 6    | 3.3 | 28   | 7.1 |
| pN status      |        |      |      |     |      |     |
| N0             | 389  | 67.3| 133  | 72.7| 256  | 64.8|
| N1             | 152  | 26.3| 41   | 22.4| 111  | 28.1|
| N2             | 37   | 6.4 | 9    | 4.9 | 28   | 7.1 |
| Grade          |        |      |      |     |      |     |
| H (well diff.) | 58   | 10.0| 19   | 10.4| 39   | 9.8 |
| M (moderate diff.) | 453 | 78.2| 127  | 69.4| 326  | 82.3|
| L (poorly diff.) | 63   | 10.9| 34   | 18.6| 29   | 7.3 |
| Mucinous diff. | 5    | 0.9 | 3    | 1.6 | 2    | 0.5 |
| Type of surgery|        |      |      |     |      |     |
| Elective       | 519  | 89.6| 171  | 93.4| 348  | 87.9|
| Acute          | 60   | 10.4| 12   | 6.6 | 48   | 12.1|

Abbreviations: diff. = differentiated; H = high; L = low; M = moderate.
Genomic instability and prognosis in CRC  

We used a Cox proportional hazards regression model. In multivariate models including CIN status we excluded MSI due to the high correlation between the two variables. Separate analysis of the prognostic impact of CIN in the first and second 5-year periods supported validity of the proportional hazard assumption. All statistics were generated using SPSS 20.0 (IBM Corporation, Armonk, NY, USA). Statistical significance was defined as two-sided \( P < 0.05 \).

The study was performed according to the Helsinki Declaration and approved by the Norwegian Regional Committees for Medical Research (REK; #1.2005.1629).

### RESULTS

**Overall survival.** Of 855 patients, 291 were alive at the end of follow-up (mean 69 months). Figure 1 shows Kaplan–Meier OS curves for all stages.

**Table 2. Time to recurrence related to prognostic factors for stage I–III and stage II colorectal cancer patients**

| Variables | Univariate analysis all | | Univariate analysis stage II | | Cox multivariate analysis all | | Cox multivariate analysis stage II |
|---|---|---|---|---|---|---|---|
| | No of pts | 5-y TTR | 10-y TTR | P-value | No of pts | 5-y TTR | 10-y TTR | P-value | HR | 95% CI | P-value | HR | 95% CI | P-value |
| Age at surgery (years) | | | | | 0.003 | | | | | 0.003 |
| <72 | 289 | 0.73 | 0.64 | | 0.001 | 130 | 0.75 | 0.65 | | 1.51 | 1.15–1.98 |
| >72 | 290 | 0.62 | 0.49 | | 0.008 | 148 | 0.67 | 0.50 | | Ref | Ref |
| DNA ploidy | | | | | 0.006 | | | | | 0.007 |
| Diploid | 183 | 0.74 | 0.66 | | 0.001 | 96 | 0.83 | 0.74 | | Ref | Ref |
| Non-diploid | 396 | 0.64 | 0.53 | | 0.001 | 182 | 0.65 | 0.49 | | Ref | Ref |
| MSI status | | | | | 0.007 | | | | | 0.007 |
| MSS | 452 | 0.65 | 0.54 | | 0.001 | 205 | 0.67 | 0.53 | | 1.51 | 1.15–1.98 |
| MSI | 87 | 0.72 | 0.64 | | 0.049 | 53 | 0.80 | 0.69 | | Ref | Ref |
| Stage | | | | | <0.001 | | | | | <0.001 |
| I | 112 | 0.85 | 0.81 | | 0.002 | Ref | Ref |
| II | 278 | 0.71 | 0.58 | | 0.986 | Ref | Ref |
| III | 189 | 0.52 | 0.41 | | 0.001 | 189 | 0.52 | 0.41 | | 3.88 | 2.36–6.39 |
| Grade | | | | | 0.002 | | | | | 0.001 |
| H (well diff.) | 58 | 0.78 | 0.74 | | 0.002 | 16 | 0.69 | 0.69 | | 1.45 | 0.84–2.52 |
| M (moderately diff.) | 453 | 0.69 | 0.58 | | 0.001 | 227 | 0.71 | 0.58 | | 2.76 | 1.46–5.22 |
| L (poorly diff.) | 63 | 0.52 | 0.40 | | 0.001 | 31 | 0.73 | 0.56 | | 2.76 | 1.46–5.22 |
| pT stage | | | | | <0.001 | | | | | 0.275 |
| pT1 | 27 | 0.88 | 0.88 | | 0.002 | 17 | 0.71 | 0.59 | | Ref | Ref |
| pT2 | 103 | 0.82 | 0.77 | | 0.002 | 103 | 0.82 | 0.77 | | 1.45 | 0.84–2.52 |
| pT3 | 415 | 0.64 | 0.52 | | 0.002 | 261 | 0.71 | 0.59 | | 1.45 | 0.84–2.52 |
| pT4 | 34 | 0.51 | 0.34 | | 0.002 | 17 | 0.65 | 0.49 | | 1.45 | 0.84–2.52 |
| Gender | | | | | 0.953 | | | | | 0.770 |
| Male | 289 | 0.67 | 0.57 | | 0.953 | 138 | 0.72 | 0.58 | | 2.04 | 1.23–3.38 |
| Female | 290 | 0.68 | 0.57 | | 0.953 | 140 | 0.70 | 0.58 | | 2.04 | 1.23–3.38 |
| Location | | | | | 0.723 | | | | | 0.483 |
| Proximal colon | 227 | 0.68 | 0.54 | | 0.723 | 129 | 0.77 | 0.58 | | Ref | Ref |
| Distal colon | 179 | 0.65 | 0.56 | | 0.723 | 82 | 0.67 | 0.58 | | Ref | Ref |
| Rectum | 173 | 0.70 | 0.62 | | 0.723 | 67 | 0.66 | 0.60 | | Ref | Ref |
| Type of surgery | | | | | <0.001 | | | | | 0.001 |
| Elective | 519 | 0.70 | 0.59 | | 0.001 | 244 | 0.73 | 0.61 | | Ref | Ref |
| Acute | 60 | 0.48 | 0.36 | | 0.001 | 34 | 0.53 | 0.38 | | 1.04 | 1.27–2.69 |

**Abbreviations:** CI = confidence interval; diff. = differentiated; H = high; HR = hazard ratio; L = low; M = moderate; No = number; pts = patients; Ref = reference; TTR = time to recurrence; y = year.
Figure 2. Kaplan–Meier plots of time to recurrence among patients presenting with stage I (A), stage II (C) and stage III (E) tumours. Each panel shows relapses for four separate categories of tumour phenotype: diploid MSI (green line), non-diploid MSI (purple line), diploid MSS (blue line) and non-diploid MSS (orange line). To the right of each panel is a table (B, D and F) showing the distribution of DNA ploidy status categories among MSI and MSS tumours in that tumour stage. A forest plot (G) summarises the effect of MSI/CIN in the different stages.
whereas the microsatellite stable (MSS) tumours were predominantly DNA non-diploid and distal.

**Recurrence.** Of the 579 patients in the TTR data set, 220 (38%) experienced recurrence (153) or died of CRC (67) after a median of 23 months (range 1–120). In stage II disease the 10-year estimated recurrence rate was 42% (Table 2). Clinicopathological features of the TTR data set are summarised in Table 1.

**CIN and recurrence.** Analysis for prognostic factors in stage II cases alone and in the entire TTR data set are shown in Table 2. As in the OS analysis, CIN status was found to be significant in univariate (P = 0.001) and multivariate analysis in stage II that included age, three levels of histology grade and emergency vs elective surgery, (HR 2.19 (1.35–3.55), P = 0.002). In the stage II TTR cohort, the independent prognostic factors for recurrence were CIN and urgency of surgery. Among the stage II patients with CIN (n = 182) 43% experienced recurrence, compared with 22% among DNA diploid stage II patients (n = 96).

In stage I tumours, we observed a similar trend as for stage II, but this difference failed to reach statistical significance, due to small patient numbers. Among stage III CRCs, no prognostic impact of CIN was found (Figure 2). This pattern was similar for both colon and rectal stage III cancers (Figure 3).

Taking stages I–III together, CIN continued to be a significant prognostic factor in univariate analysis (P = 0.006) and it retained significance as an independent prognostic factor in Cox multivariate analysis (HR 1.56 (1.13–2.15), P = 0.007).

In order to investigate the effect of heterogeneity for CIN between the three stage groups we included the interaction term CIN’s stage in the Cox regression model and found that both the interaction term and stage were significant in the model, while CIN was not. We may interpret this as stage having an effect regardless of CIN status, while the effect of CIN is different in the three stage groups. The prognostic effect of CIN in the three stage groups is illustrated in Figure 4.

**MSI and recurrence.** The positive prognostic impact of MSI among stage II, but not stage III, colorectal tumours from the present material has already been reported (Merok et al, 2013). In our TTR data set, MSI was borderline significant (P = 0.049) in univariate analysis, but not significant (P = 0.094) in multivariate analysis in stage II (Supplementary Table S3).

Figure 2 shows Kaplan–Meier plots for relapse of the different combinations of MSI and CIN status as stratified by stage. Tables in the same figure show how the relationship between MSI/MSS and DNA ploidy status was dependent on stage. There were no relapses among the 10 patients with stage I MSI tumours. Fifty-three patients presented with stage II MSI tumours, of which 37 were diploid, 3 were aneuploid and 13 were tetraploid. The relatively good prognosis of the 104 MSI and diploid MSS stage II lesions contrasted with the poor prognosis of 154 patients with the CIN-MSS phenotype. Patients with stage III tumours had a uniformly high level of relapse that was independent of both MSI and CIN.

Figure 3 compares the stage-dependent prognostic impact of MSI with that of CIN in the colon and rectum. Among stage II lesions in both locations non-diploid MSI tumours show a significantly increased probability of relapse. As reported elsewhere, MSI tumours were rare in the rectum (5 of 173 tumours). In the colon, diploid MSS tumours had similar relapse rates to MSI tumours.

In total, 133 (25%) of the patients did not follow the diploid/MSI-non-diploid/MSS pattern.

### DISCUSSION

This study is the first to report survival data in relation to CIN/MSI after stratifying according to tumour stage. In fact few survival studies have measured CIN and MSI in the same resection specimens. Supplementary Table S4 summarises some relevant findings from eight studies as well as from the present report. Despite the often quoted ‘typical incidence’ figures of 85% CIN and 15% MSI in CRC, the incidence of CIN varied between 35–70% in these studies, while MSI varied from 5–23% and tumours showing neither CIN nor MSI were common (19–52%). In the light of the present finding of a marked stage-specific difference in the prognostic impact of both CIN and MSI, the variability between results in Supplementary Table S4 can be seen as following inclusion of different proportions of stage I–IV material in the different studies.

Twenty-five per cent of the stage II cancers with MSI in this study were DNA tetraploid, and these carried good prognosis equal to that of the other MSI tumours (Figure 2). The biological basis of this difference from MSS tetraploidy remains to be clarified. There are advantages and disadvantages with all end points. For OS, non-cancer-related deaths add variability. This is to some degree taken into account by censoring at 5 years after surgery. With TTR, inclusion of cancer-related deaths is controversial as this is often hard to demonstrate. However, the main conclusions regarding CIN and MSI remain the same regardless of end point, although P-values and hazard ratios change to some degree. Supplementary Figure S1 illustrates this for CIN in the data sets representing both OS and TTR end points. For direct comparison with the previously published work on MSI status in this material we include figures in Supplementary Figure S1 for the prognostic impact of CIN using the 5-year relapse free survival (RFS) model employed by Merok et al (2013). Interestingly, the 5-year RFS P-values for CIN status are higher than the corresponding P-values for OS and TTR. A possible explanation is that CIN has a
continuing prognostic impact after 5 years, which is not taken into account with the 5-year end point.

We report that stage II tumours with MSI have very similar prognosis to diploid MSS lesions. CIN occurred more often than MSI, and both CIN and MSI were confirmed in our TTR analysis as independent predictors of recurrence in stage II CRC. Although rarely occurring outside of the proximal colon, MSI is currently seen as a clinically useful predictor of good outcome for patients with stage II CRC. This is supported by positive results from retrospective trials such as the present study in which multivariate analysis shows MSI to have significant predictive value. But from the point of view of an individual patient, the clinical picture is less than ideal – we found MSI in only 51 of the stage II resections in this study, and 13 of these patients went on to experience recurrence. As for CIN, our results support the present consensus that CIN is also an independent prognostic marker in stage II CRC, and possibly a more useful marker than MSI (Sinicrope et al, 2006; Mouradov et al, 2013). But again, from the individual patient’s point of view CIN is less ideal. Of the 182 stage II resections with CIN in the TTR cohort, 75 were associated with relapse, while there were 23 recurrences among the 96 patients with diploid resections. Adding CIN to the MSI results produced only a small improvement in prediction for relapse. Can the clinical usefulness of DNA cytometry be improved? This remains a very promising area for research. Here we have used the most robust binary DNA histogram classification (CIN or DNA diploid), but it is clear that a great deal more information still remains to be extracted from the Feulgen images of tumour nuclei (Dunn et al, 2011).

ACKNOWLEDGEMENTS

The technical assistance of Jeanne D’Arc Karerwa, Åsmund Nybøen, Marna Lilj Kjæreng and Helene Kile Larsen is greatly appreciated.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

Ågesen TH, Sveen A, Merok MA, Lind GE, Nesbakken A, Skotheim RI, Lothe RA (2012) ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. Gut 61(11): 1560–1567.
Araujo SE, Bernardo WM, Habr-Gama A, Kiss DR, Cecconello I (2007) DNA ploidy status and prognosis in colorectal cancer: a meta-analysis of published data. Dis Colon Rectum 50(11): 1800–1810.
Barrier A, Roser F, Boelle PY, Franc B, Tse C, Broult D, Lacaine F, Houry S, Callard P, Pena C, Debuire B, Flahault A, Dudoit S, Lemoine A (2007) Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling. Oncogene 26(18): 2642–2648.
Domingo E, Ramamoorthy R, Oukrif D, Rosmarin D, Presz M, Wang H, Pulker H, Lockstone H, Hveem T, Cranston T, Danielsen H, Novelli M, Davidson B, Xu ZZ, Molloy P, Johnstone E, Holmes C, Midgley R, Kerr D, Sieber O, Tomlinson I (2013) Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. J Pathol 229(3): 441–448.
Dunn JM, Hveem T, Pretorius M, Oukrif D, Nielsen B, Albrechtson F, Lovat LB, Novelli MR, Danielsen HE (2011) Comparison of nuclear texture analysis and image cytometric DNA analysis for the assessment of dysplasia in Barrett’s oesophagus. Br J Cancer 105(8): 1218–1223.
Gangadhari T, Schilsky RL (2010) Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol 7(6): 318–325.
Guastadisegni C, Colafranceschi M, Ottini L, Dogliotti E (2010) Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur J Cancer 46(15): 2788–2798.
Hawkins NJ, Tomlison I, Meagher A, Ward RL (2001) MSI is a marker of prognosis and relapse in colorectal cancer. Eur J Cancer 37(1): 232–236.
Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ (2004) Cancer statistics, 2004. CA Cancer J Clin 54(1): 8–29.
Kristensen GB, Kildal W, Abelcer YM, Kerv J, Vergote I, Tropé CG, Danielsen HE (2003) DNA damage and DNA ploidy status and prognosis in colorectal cancer: a meta-analysis. Br J Cancer 89(10): 1740–1745.
Lengauer C, Kinzler KW, Vogelstein B (1998) Genetic instability in human cancers. Nature 396(6712): 643–649.
Merok MA, Ahlquist T, Røyvik EC, Tufteland KF, Hektoen M, Sjo OH, Mala T, Svindland A, Lothe RA, Nesbakken A (2013) MSI is a marker of prognosis and relapse in colorectal cancer. Eur J Cancer 48(15): 3089–3100.
Mouradov D, Domingo E, Gibbs P, Jorissen RN, Li S, Soo PY, Lipton L, Desai J, Danielsen HE, Oukrif D, Novelli M, Yau C, Holmes CC, Jones JT, McLaughlin S, Molloy P, Hawkins NJ, Ward R, Midgley R, Kerr D, Tomlison IP, Sieber OM (2013) Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. Ann J Gastroenterol 108(11): 1785–1793.
Nesbakken A, Nygaard K, Westerheim O, Mala T, Lunde OC (2002) Local recurrence after mesorectal excision for rectal cancer. Eur J Surg Oncol 28(2): 126–134.
Punt CJ, Buyse M, Kohne CH, Hohenberger P, Labianca R, Schmoll HJ, Pahlman L, Sobero A, Douillard JY (2007) Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 99(13): 998–1003.
Sinicrope FA, Rego RL, Halling KC, Foster N, Sargent DJ, La PB, French AF, Laurie JA, Goldberg RM, Thibodeau SN, Witzig TE (2006) Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 131(3): 729–737.
Sjo OH, Lunde OC, Nygaard K, Sandvik L, Nesbakken A (2008) Tumour location is a prognostic factor for survival in colonic cancer patients. Colorectal Dis 10(1): 33–40.
Staal L, Link KH, Blatz A, Beger HG (2002) Surgery of colorectal cancer: surgical morbidity and five- and ten-year results in 2400 patients–monoinstitutional experience. World J Surg 26(1): 59–66.
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)